Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Mayo Clinic
University of Kentucky
BeiGene
University Health Network, Toronto
Alliance for Clinical Trials in Oncology
ImmunoGenesis
Bristol-Myers Squibb
Fundación GECP
Checkpoint Therapeutics, Inc.
EpicentRx, Inc.
Novartis
Novartis
M.D. Anderson Cancer Center
Eisai Inc.
University of Washington
Barbara Ann Karmanos Cancer Institute
Innovent Biologics (Suzhou) Co. Ltd.
Hoosier Cancer Research Network
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Barbara Ann Karmanos Cancer Institute
Regeneron Pharmaceuticals
Massachusetts General Hospital
Mereo BioPharma
National Institutes of Health Clinical Center (CC)
University of Maryland, Baltimore
Eli Lilly and Company
Eli Lilly and Company
Novartis
Incyte Corporation
Northwestern University
M.D. Anderson Cancer Center
Mayo Clinic
University of California, Davis
Memorial Sloan Kettering Cancer Center
EMD Serono
University of California, Davis
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Roswell Park Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Tufts Medical Center
University of Washington
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Alliance for Clinical Trials in Oncology